Scopio Labs

Key People

• Itai Hayut - Co-Founder and CEO
• Erez Na'aman - Co-Founder and CTO
• Amir Shlomovich - Chief Operations Officer
• Yossi Maimon - Chief Financial Officer
• Iris Getz - Chief Strategy Officer
• Amir Farhi - Chief Commercial Officer
• Amy Meitus MD - Chief Product Officer
• Guy Meger - SVP R&D
• Tali Cohen - VP HR
• Jordan Feder - VP Business Development
• Roei Samuri - VP Supply Chain
• Lianne Trantz - VP Marketing
• Etty Shneorson - VP Customer Success
• Tzahi Madgar - VP of Corporate Partnerships

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in physics, electro-optics, and medical device technology.

The co-founders, Itai Hayut and Erez Na'aman, have backgrounds in physics and electro-optics, providing a strong foundation for developing advanced medical imaging technologies. Their experience and vision have been instrumental in driving the company's success.

Clinical Need

Aspect: Very Strong
Summary: Scopio Labs addresses a critical need in hematology by digitizing and automating cell morphology analysis, enhancing diagnostic accuracy and efficiency.

Traditional manual microscopy in hematology is labor-intensive and prone to variability. Scopio Labs' digital imaging and AI solutions streamline this process, providing faster and more accurate diagnoses, which is crucial for patient outcomes.

Competition

Aspect: Somewhat crowded
Summary: The market includes established players like CellaVision, Horiba Medical, and Sysmex, all offering digital cell morphology solutions.

Competitors have significant market presence and resources. However, Scopio Labs' full-field digital imaging and AI integration provide distinct advantages that can differentiate it in the market.

Technical Challenge

Aspect: Predictable
Summary: The development of high-resolution digital imaging and AI analysis for hematology is complex but manageable with current technologies.

Scopio Labs has successfully developed and implemented its technology, indicating that while challenges exist, they are within the realm of current technical capabilities and can be addressed effectively.

Patent

Aspect: Strong
Summary: Scopio Labs holds patents for its full-field digital imaging technology, providing a competitive advantage.

Patents protect the unique aspects of Scopio Labs' technology, preventing competitors from easily replicating their solutions and allowing the company to maintain a strong foothold in the market.

Financing

Aspect: Well-funded
Summary: With a total funding of $145M, including a recent $52M Series D round, Scopio Labs is well-capitalized to support its growth and development plans.

Adequate financing is crucial for scaling operations, advancing technology, and penetrating new markets. Scopio Labs' funding positions it well to achieve these objectives.

Regulatory

Aspect: 510k/PMA
Summary: Scopio Labs has obtained FDA clearance and CE marking for its Full-Field Peripheral Blood Smear Application, facilitating market entry in the U.S. and Europe.

Achieving regulatory clearances demonstrates compliance with industry standards and allows the company to market its products in key regions, building trust with customers and stakeholders.

Opportunity Rollup

Odds of Success

3.7

Peak Market Share

4.7

Segment CAGR

2.9%

Market Segment

Diagnostic Imaging

Market Sub Segment

Hematology Diagnostics

Key Takeaway

Scopio Labs is well-positioned in the hematology diagnostics market with its innovative digital imaging and AI solutions, supported by strong leadership and substantial funding.